Natco Pharma up 5% on filing new drug applications with USFDA

Shares of Natco Pharma rose by over 5 per cent on filing new product applications with the US health regulator for generic version of drugs used in the treatment of nervous system disease and cancer.
The stock ended the day at Rs 1,434.15, up 5.49 per cent on the BSE. During the day, it climbed 8.37 per cent to Rs 1,473.40.
On the NSE, it rose by 3.99 per cent to settle at Rs 1,420.10.
The company has filed Abbreviated New Drug Applications (ANDAs) for Fingolimod, 0.5 mg capsules and Cabazitaxel, 60mg/ 1.5ml injection, with the US Food and Drug Administration, through its respective marketing partners, Natco Pharma said in a filing to the BSE.

"Natco and its associated marketing partners for the above products in the US, believe that they are the first company to have filed a substantially complete ANDA which includes a paragraph IV certification for Fingolimod capsules and Cabazitaxel injection, providing 180 days of marketing exclusivity upon its final USFDA approval," it added.